Table 1.
Treatment groups.
| Group Name | Group | Genotype^ | Pilocarpine or control (no SE) | DTr | DT treatment? | Ablation occurred? | Males (n) | Females (n) |
|---|---|---|---|---|---|---|---|---|
| Healthy Control | A | NestinCreERT2+/*; DTr−/− or NestinCreERT2 −/−; DTr+/− | Healthy | DTr negative | DT | NO | 2 | 3 |
| B | NestinCreERT2+/*; DTr+/− | Healthy | DTr positive | Ringer’s | NO | 3 | 2 | |
| Healthy Ablation | C | NestinCreERT2+/*; DTr+/− | Healthy | DTr positive | DT | YES | 5 | 5 |
| SE Control | D | NestinCreERT2+/*; DTr−/− or NestinCreERT2 −/−; DTr+/− | Epileptic | DTr negative | DT | NO | 3 | 1 |
| E | NestinCreERT2+/*; DTr+/− | Epileptic | DTr positive | Ringer’s | NO | 3 | 2 | |
| SE Ablation | F | NestinCreERT2+/*; DTr+/− | Epileptic | DTr positive | DT | YES | 4 | 4 |
Treatment descriptions and the number of male and female mice present in each animal group. *NestinCreERT2 expressing mice are all hemizygous. ^GFP reporter genotype not shown. Tamoxifen treatments (not shown) were identical in all mice. SE, status epilepticus. DTr, diphtheria toxin receptor. DT, diphtheria toxin.